Latham-led Deal Shortlisted for the Scrip Awards’ Quris Best Partnership Alliance Honor

Leading pharmaceutical intelligence and research company Citeline has shortlisted the strategic collaboration between Sonoma Biotherapeutics and Regeneron Pharmaceuticals in the Quris Best Partnership Alliance category as part of its prestigious Scrip Awards program.

Latham’s healthcare and life sciences team, led by Bay Area partners Judith Hasko and Mark Roeder, advised Sonoma Biotherapeutics in the collaboration with Regeneron to apply their collective scientific and clinical expertise and respective technology platforms to the discovery, development, and commercialization of novel regulatory T cell therapies for autoimmune diseases. The collaboration brings together Regeneron’s industry-leading VelociSuite® technologies for the discovery and characterization of fully human antibodies and T cell receptors with Sonoma Biotherapeutics’ pioneering approach to developing and manufacturing gene-modified Treg cell therapies.

Now in its 19th year, the Scrip Awards recognize the very best innovations and achievements in global biopharma. The Quris Best Partnership Alliance category recognizes the importance of pharmaceutical and/ or biotech companies working together to develop new medicines.